- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Animal tests have shown that even minute particles with a diameter of one millimeter or less can cause serious harm. The vascular area where the emboli goes determines whether or not embolisation results in a deficit.
Some parts of the brain serve no clear purpose. This explains why cerebral embolism happens so often with no clinical implications.
Distal embolisation is not just a consequence of carotid interventions, but it is also prevalent during saphenous vein graft operations and acute myocardial infarction procedures, according to new research.
There is currently no data examining the frequency of embolism with renal procedures. However, Al-Halmali et al.
published a study that looked at Doppler signals over the femoral arteries during iliac procedures and used the results of Doppler signals over the femoral arteries.
Despite the fact that the patients who underwent renal percutaneous transluminal angioplasty (PTA) were the control group and the number of embolic signals was significantly lower than in the patients who underwent iliac PTA, this small clinical study was able to show that a significant amount of debris is released during renal interventions, which could affect the renal circulation.
There are three types of embolic protection devices for carotid interventions: filters, distal occlusion devices, and proximal occlusion devices. Following sheath installation, filters and distal occlusion balloons are inserted.
It may be difficult to place in the twisted carotid arteries. A proximal embolic protection device should be used in these circumstances. Although the present available filters have an acceptable crossover profile, it may be improved.
In tight and calcified carotid lesions, a more flexible distal occlusion device with a crossing profile or a proximal occlusion device may be more appropriate.
Except for the Rubicon filter and the newest generation Interceptor filter, all filters are delivered by a delivery catheter inserted through the sheath.
The retrieval catheter is withdrawn when the filter has been opened. The filter wire serves as a guidewire for balloon dilatation and stent placement.
The novel Fibernet (Lumen Biomedical) technology, which is presently only accessible in a clinical study, combines the benefits of occlusion and filter systems.
It is made of a pore-sized matrix of polyethylene terephthalate (PET) fibers and, like the Rubicon filter, does not require a delivery sheath.
During device removal, debris is aspirated using the retrieval catheter.When using distal occlusion devices, debris must be aspirated out before deflating the balloon.
The novel Triactiv distal embolic protection system combines active flushing and extraction to remove debris from the treated region.
Proximal occlusion devices, such as the MO.MA device (Invatec) and the Gore Neuroprotection System (Gore), use an occlusion balloon to occlude the external and common carotid arteries. Carotid angioplasty can be conducted as normal using the guiding catheter.
As with distal occlusion devices, debris must be evacuated before releasing the occlusion balloon following angioplasty.
The PercuSurge GuardWire was the first embolic protection device tested in deteriorated saphenous vein grafts in the Saphenous Vein Graft Angioplasty Free of Emboli, Randomised study.
When compared to operations without protection, there was a considerable reduction in the risk of -day serious adverse cardiac events.
During saphenous vein graft procedures, the FIRE study compared FilterWire filter devices to GuardWire balloon occlusion devices. In terms of peri-procedural danger, the devices showed to be equal.
In patients with acute myocardial infarction having urgent percutaneous coronary intervention, some small studies using distal protective devices yielded positive outcomes.
As evaluated by enhanced myocardial perfusion by angiography and improved ST-segment elevation resolution following PCI, the use of embolic protection devices reduced slow-flow, no-reflow, and distant embolisation.
There is a scarcity of evidence on embolic protection during renal procedures. The feasibility and safety of distal occlusion and filter devices during renal interventions were demonstrated in two single-center trials.
However, large randomized studies are needed to establish their effectiveness in preventing embolism and loss of renal function.
During the majority of operations, embolic protection devices catch arteriosclerotic material discharged during angioplasty and stenting. These instruments are, without a doubt, a vital element of the treatment, according to experts.
There is currently evidence that using embolic protection devices during carotid and saphenous vein transplant operations decreases peri-procedural complication rates considerably. Furthermore, studies of single-center clinical trials in native coronary arteries and renal arteries.
The Global Carotid Embolic Protection Systems Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The sixth-generation Emboshield NAV6 Embolic Protection System from Abbott has been released for use in carotid artery stenting procedures.
Carotid artery stenting is a minimally invasive therapy option to traditional open carotid artery surgery for people who are at high surgical risk.
During the stenting process, embolic protection devices are employed to prevent particles of dislodged plaque from entering the brain and potentially triggering an ischemic stroke. The Emboshield NAV6 is now available in North America and Europe.
The Emboshield NAV6 builds on the Emboshield product family's excellent legacy while enhancing deliverability and ease of use for clinicians.
Abbott's patented BareWire technology permits wire movement independent of the Emboshield NAV6 filter, allowing clinicians greater control during carotid artery stenting.
The Emboshield NAV6's unique design significantly improves on an already effective embolic protection technology.
It has great steerable wire choices for independently reaching difficult lesions, a short basket length, considerably increased visibility, a simpler retrieval mechanism, and perfect pore size and distribution. These enhancements make the NAV6 system an exceptional embolic protection technology.
The Emboshield NAV6 fulfilled both safety and effectiveness goals in Abbott's Protect clinical study, which was meant to assess carotid artery stenting using Abbott's Emboshield devices in patients at high risk for endarterectomy (surgery).
The Protect research results demonstrated a low percent composite risk of All Stroke and Death, in addition to exhibiting continuous improvements in outcomes for carotid stent surgeries. This rate is well within the American norm.
30-day All Stroke and Death Rate Guidelines from the American Heart Association (AHA) for carotid endarterectomy in symptomatic and asymptomatic individuals with carotid artery disease.
he findings of the Protect trial were presented at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC.
Abbott is the global leader in carotid artery stenting. More than 100,000 patients have been treated with Abbott's carotid stents and embolic protection systems worldwide since the initial carotid stent approval.
The new Emboshield NAV6 adds to the arsenal of therapies for treating carotid artery disease, a key cause of stroke.
Abbott has created a diverse portfolio of technologies to assist physicians in providing better care to their patients with peripheral artery disease. The firm is devoted to investing in endovascular technologies.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.